Moderna on Monday lowered its 2025 sales guidance by roughly $1 billion due to a few potential headwinds later this year, as the biotech company continues to cut costs and expand its portfolio.Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year. The majority of those sales will come from Moderna's Covid shot and newly launched vaccine for respiratory syncytial virus, according to a release.The guidance is down from a prior ...

财务预测与数据 - 公司2024财年产品销售额预计为30-31亿美元[4] - 公司截至2024年12月31日的现金、现金等价物及有价证券投资预计约为95亿美元[4] 财务审计与责任 - 公司财务数据尚未完成审计，可能存在变动[5] - 公司信息未根据《证券交易法》第18条被视为“提交”，也不承担相关责任[7] 公司公告与披露 - 公司发布了2025年1月13日的新闻稿，作为8-K表格的附件[9]

Delhi, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Global mRNA Cancer Vaccines Clinical Trials and Market Future Outlook 2024 Report Highlights: mRNA Cancer Vaccines In Clinical Trials: > 60 VaccinesHighest Phase Of Clinical Trials: Phase III ( 2 Vaccine)mRNA Cancer Vaccine Clinical Trials Insight By Company, Country, Indication and PhaseFirst Commercial mRNA Vaccine Approval Expected By 2029US and China Dominating mRNA Cancer Vaccines Clinical Trials: > 45 VaccinesmRNA Vaccines For Skin Cancer Dominating Trials: > 1 ...

Shares of Moderna Inc. NASDAQ: MRNA surged over 12% after news of the first confirmed death from the H5N1 bird flu in the United States. At one point, the stock had climbed over 14% before returning late in the trading session. However, the stock retreated after hours, trading at $47.53, and has since declined further. Moderna TodayMRNAModerna$44.56 -2.97 (-6.25%) 52-Week Range$35.80▼$170.47Price Target$78.83Add to WatchlistGet Moderna alerts:Which isn’t to say there’s no correlation. The company did recei ...

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi ... [+] Images/GHI/UCG/Universal Images Group via Getty Images)UCG/Universal Images Group via Getty ImagesThe stock price of Moderna saw a 12% jump on Tuesday, January 7, amid rising cases of Covid-19 and flu in the U.S. Along with Moderna, stocks of other vaccine makers also saw an uptick. Novavax was up 11%, while BioNTech ADR was up 5%. According to the CDC, influenza’s test positivity rate increased from 13.6% for the w ...

Introduction of a Universal Coronavirus Vaccine: A robust cross-immunity effect to combat virus mutations.SEOUL, South Korea, Jan. 8, 2025 /PRNewswire/ -- The COVID-19 pandemic has fundamentally transformed global healthcare systems and vaccine technologies. The accelerated approval and rapid distribution of mRNA vaccines introduced a new paradigm in infectious disease response, highlighting the need for swift action.Despite the success of mRNA vaccines, the unmet needs include limited effectiveness agains ...

After undergoing years of stock market decline as reporting and awareness about the COVID-19 pandemic subsided, major vaccine stocks received a major, if grim, boost in early 2025.Specifically, researchers have been tracking with growing concern the ill-documented spread of new H5N1 (Avian Influenza or Bird Flu) variants, with some even warning that the U.S. has completely lost track of the illness by late 2024.Indeed, multiple health experts have spoken about insufficient tracking of contagion, with many c ...

Moderna (MRNA) shares soared 11.7% in the last trading session to close at $47.53. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.8% loss over the past four weeks.The surge in stock price came as investors turned their attention toward the potential demand for vaccines targeting the H5N1 virus, also known as bird flu. On Monday, the U.S. CDC reported the first human death in the country from bird flu. The company is currently ...

Key TakeawaysModerna shares soared Tuesday as investors placed bets that the pharmaceutical giant’s development of an H5N1 bird flu vaccine could boost sales after the first death linked to the disease was reported in the U.S. The stock closed decisively above the closely-watched 50-day moving average today on the highest volume since December’s triple witching trading session.Investors should watch significant overhead areas on Moderna's chart around $57, $72, and $85, while also monitoring important suppo ...

Without our health… time to look at Moderna’s stock (NASDAQ: MRNA).In my Outlook 2025, I list 10 stock picks. I also end the picks section with Honorable Mention stocks that I describe as “These stocks faced challenges in 2024, but as we approach 2025, they show promising fundamentals and charts with clear support levels and obvious breakout points.”Moderna (MRNA) is first on that list. Sign up for our FREE newsletter and receive our best trading ideas and research Leave this field empty if you're ...